ArticleSchizophrenia research2024
The COMPASS scale for the assessment of individuals with first episode psychotic disorders.
Article in Schizophrenia research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Persistent Negative Symptoms: Characterization of an Unmet Need in a Learning Health System for First-Episode Psychosis.Schizophrenia bulletin · 2026Article
- A pilot study of BRAVE, a CBT intervention to reduce violence risk in early psychosis.Cognitive behaviour therapist · 2026Article
- The problem of missing data for learning health systems focused on first-episode psychosis.Schizophrenia research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPsychosis symptom assessment instruments are rarely used in US mental health community clinical practice despite the advantages of measurement-based care. Barriers include the length of typical scales and that data for scale evaluation often come from researcher and not clinician raters. STUDY
designThe 12-item COMPASS symptom assessment was designed for the RAISE-ETP study of early phase psychosis. Ratings were done by community facility clinicians. COMPASS psychometric properties were examined with a Mokken scale analysis. Subsequently, Mokken analyses were done on 10-item COMPASS data from the ESPRITO learning health system. STUDY
results3600 RAISE-ETP COMPASS assessments were examined. The COMPASS 12-item version fulfilled Mokken scale criteria for unidimensionality (H = 0.329 (SE:0.007)) as did a derived reduced 10-item version (H = 0.359 (SE:0.007)) and 5-item version (H = 0.396 (SE = 0.009)). The 12-item version showed one significant monotonicity violation; no significant violations were found in the reduced item versions. Of the reduced item versions, clinicians preferred the 10-item over the 5-item version. In the ESPRITO data, both the 10-item and 5-item versions met unidimensionality criteria (H = 0.458 (SE:0.030) and 0.478 (0.034) respectively) with no monotonicity violations.
conclusionsThe COMPASS scale offers clinicians versions with varying lengths for assessment of individuals with first episode psychotic disorders in community settings. COMPASS can also facilitate data collection for large scale initiatives; the 10-item version is a symptom assessment option in the US national EPINET project.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.